Aegis Capital Keeps BioLineRx (BLRX) at 'Buy' Following Q2 Results; Plenty of Catalysts Ahead
Tweet Send to a Friend
Aegis Capital affirms BioLineRx, Ltd. (Nasdaq: BLRX) at Buy with a price target of $7 following Q2 results.Analyst Ram Selvaraju ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
